Heart Failure Clinical Trial
— DYNAMICOfficial title:
A Randomized, Double-blind, Placebo-controlled, Phase I Study of the Safety of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)
Verified date | June 2016 |
Source | Capricor Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
To determine the safety profile of CAP-1002 administered by multi-vessel intracoronary infusion in subjects with DCM. The study will further explore safety and exploratory efficacy endpoints of CAP-1002.
Status | Active, not recruiting |
Enrollment | 42 |
Est. completion date | April 2020 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Major Inclusion Criteria: 1. DCM with left ventricular ejection fraction (LVEF) = 35% as determined by a historical TTE within the previous 6 months 2. New York Heart Association (NYHA) Class III or ambulatory Class IV heart failure 3. Use of evidence based medical-therapy (beta-blockers, ACE-inhibitors/angiotensin receptor blockers, aldosterone antagonist) and with or without device-therapy (Implantable cardioverter-defibrillator or cardiac resynchronizing therapy), in accordance with the ACC/AHA guidelines for the management of heart failure, for at least three months prior to enrollment or documented contraindication or intolerance or patient preference 4. Coronary anatomy suitable for Investigational Product (IP) infusion, as determined by the Eligibility Committee (a team of cardiology experts) 5. Ability to provide informed consent and follow-up with protocol procedures 6. Screening cardiac CT left ventriculogram ejection fraction <40% with left ventricular dilatation 7. Age = 18 years Major Exclusion Criteria: 1. Diagnosis of active myocarditis 2. Immunologic incompatibility with all available Master Cell Banks (MCBs) by single-antigen bead (SAB) serum antibody profiling 3. Left Ventricular Assist Devices (LVAD) or those actively in the process of acquiring one 4. Recent placement of a cardiac pacemaker and/or resynchronization pacing therapy within the past three months or those actively in the process of acquiring one 5. History of sustained ventricular tachycardia (VT) requiring cardiopulmonary resuscitation (with the exception of subjects who subsequently received an ICD) 6. Non-cardiovascular disease with life expectancy of < 3 years 7. Known hypersensitivity to contrast agents 8. Estimated glomerular filtration rate (GFR) < 50 mL/min 9. Active infection not responsive to treatment 10. Active allergic reactions, connective tissue disease or autoimmune disorders 11. History of cardiac tumor, or cardiac tumor demonstrated on screening 12. History of previous stem cell therapy 13. History of treatment with immunosuppressive agents, including chronic systemic corticosteroids, biologic agents targeting the immune system, anti-tumor and anti-neoplastic drugs or anti-vascular endothelial growth factor (VEGF) within 6 months prior to enrollment (not including drug eluting coronary stents) 14. History of receipt of chemotherapeutic agents known to be implicated in cardiac dysfunction [Adriamycin, trastuzumab (Herceptin)] 15. Known moderate-severe aortic stenosis/insufficiency or severe mitral stenosis/regurgitation 16. Participation in an on-going protocol studying an experimental drug or device 17. Current active alcohol or drug abuse or inability to comply with protocol-related procedures 18. Pregnant/nursing women and women of child-bearing potential without use of active and highly reliable contraception 19. Known history of Human Immunodeficiency Virus (HIV) infection 20. Known history of chronic viral hepatitis 21. Abnormal liver function (serum glutamic pyruvic transaminase (SGPT) > 10 times the upper reference range) and/or abnormal hematology (hematocrit < 25%, white blood cells (WBC) < 3000 µl, platelets < 100,000 µl) studies without a reversible, identifiable cause 22. Evidence of tumor on screening of chest/abdominal/pelvic (body) CT scan 23. Any prior organ transplant 24. Being actively listed for, or under active consideration (i.e., work-up) for, a solid organ transplant of any kind 25. Known hypersensitivity to bovine products 26. Known hypersensitivity to dimethyl sulfoxide (DMSO) 27. Any malignancy within past 2 years (except for in-situ non-melanoma skin cancer and in-situ cervical cancer) 28. Any prior radiation therapy/treatment to the chest 29. Uncontrolled diabetes (HbA1 >9.0) 30. Any condition or other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for the study |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Cedars-Sinai Medical Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Capricor Inc. | Cedars-Sinai Medical Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects that experience new TIMI flow 0-2 or TIMI myocardial perfusion grade (TMPG) 0-2. | Intraprocedural | Yes | |
Primary | Proportion of subjects that experience acute myocarditis, possibly attributable to CAP-1002. In order to be considered related to CAP-1002, humoral or cellular or immune reaction specific to CAP-1002 must also be documented. | Within one month of intracoronary infusion | Yes | |
Primary | Proportion of subjects that experience ventricular tachycardia or ventricular fibrillation resulting in death, appropriate discharge of an ICD or requiring medical intervention. | During or within 72 hours of intracoronary infusion | Yes | |
Primary | Proportion of subjects that experience sudden unexpected death occurring within one hour of symptom onset, or un-witnessed death in a person previously observed to be well within the preceding 24 hours without an identified cause. | During or within 72 hours of intracoronary infusion | Yes | |
Primary | Proportion of subjects that experience major adverse cardiac events (MACE), including death, non-fatal myocardial infarction and re-hospitalization for cardiovascular event (including heart failure hospitalizations). | During or within 72 hours of intracoronary infusion | Yes | |
Secondary | Acute myocarditis possibly attributable to CAP-1002. In order to be considered related to CAP-1002, humoral or cellular immune reaction specific to CAP-1002 must also be documented. | During the six & twelve month follow-up period | Yes | |
Secondary | Ventricular tachycardia or ventricular fibrillation resulting in death or requiring medical intervention or appropriate discharge of an ICD. | During the six & twelve month follow-up period | Yes | |
Secondary | Sudden unexpected death defined as occurring within one hour of symptom onset, or unwitnessed death in a person previously observed to be well within the preceding 24 hours without an identified cause. | During the six & twelve month follow-up period | Yes | |
Secondary | Major adverse cardiac events (MACE), including death, non-fatal myocardial infarction, hospitalization for cardiovascular event, emergency room treatment for heart failure, left ventricular assist device or heart transplant. | During the six & twelve month follow-up period | Yes | |
Secondary | Any hospitalization due to a cardiovascular cause or related to CAP-1002 (or placebo in Phase Ib). | During the six & twelve month follow-up period | Yes | |
Secondary | Any inter-current cardiovascular illness or one related to CAP-1002 (or placebo in Phase Ib) which prolongs hospitalization. | During the six & twelve month follow-up period | Yes | |
Secondary | Development of, or an increase in the frequency of, VT with a duration of 30 seconds or longer ascertained by protocol-mandated ECG ambulatory monitoring. | During the six & twelve month follow-up period | Yes | |
Secondary | Development of increased anti-Human Leukocyte Antigen (HLA) antibody levels with development of sensitization to HLA antigens specific to the CAP-1002 CDC donor at immunologically significant titers. | During the six & twelve month follow-up period | Yes | |
Secondary | Total number of appropriate ICD firings. | During the six & twelve month follow-up period | Yes | |
Secondary | Peak elevation in troponin and CKMB levels following CAP-1002 or placebo infusion. | Through Month 1 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|